Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.
Austrian biotech Marinomed is taking its red seaweed-based Carragelose platform into new OTC categories as it steps up efforts to achieve operating profitability.
With nasal sprays containing Carragelose – authorized as class I medical devices in the EU – marketed for the prophylaxis and treatment of viral respiratory infections, the company
Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.
A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.
US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.
CRN/Radicle Science expand Trailblazer Award nominations; BodyArmor brand relaunch with ‘Choose Better’ campaign and pro athletes; and Just Ingredients catches Bryce Harper as partner.
Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.
Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.
US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.
